PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
Status:
Terminated
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy
and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to
80 years of age with PAH.
Phase:
Phase 2
Details
Lead Sponsor:
Complexa, Inc.
Collaborators:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Cardiovascular Clinical Science Foundation Clinical Works Innovative Analytics Medpace, Inc. MicroConstants Philips Healthcare